Ace Therapeutics provides customized hemorrhagic stroke models and CRO services to empower researchers worldwide to unravel the complexities of ICH and accelerate the development of life-saving treatments.

NEW YORK, NY, January 24, 2026 /24-7PressRelease/ -- Ace Therapeutics, an industry leader in preclinical stroke research services, provides customized hemorrhagic stroke models and CRO services to empower researchers worldwide to unravel the complexities of ICH and accelerate the development of life-saving treatments.

ICH's devastating impact stems from its intricate pathophysiology, including hematoma expansion, neuronal cell death, oxidative stress, blood-brain barrier (BBB) disruption, and neuroinflammation. To tackle these challenges, preclinical models that accurately replicate key disease mechanisms are indispensable. Ace Therapeutics' service portfolio encompasses both in vitro and in vivo models, each tailored to support diverse research objectives—from high-throughput screening to in-depth mechanistic analysis and preclinical efficacy testing.

In Vitro Models: Precision for Mechanistic and Screening Research
Ace Therapeutics' in vitro ICH models are designed to simplify complex biological systems while retaining critical disease-relevant features, making them ideal for high-throughput screening and targeted pathway research. Key models include:

Hemoglobin models: Reliably reflecting hematoma expansion, these models enable studies on iron dynamics and hemoglobin proteolysis, with the advantage of ease of use for large-scale screening.

Hemin models: Mimicking core secondary injury pathways such as BBB disruption and neuroinflammation, offering a reliable tool for evaluating interventions targeting these processes.

Autologous blood models: Replicating the full hemotoxicity of ICH, providing a physiologically relevant platform for studying blood-induced brain injury.

Each in vitro model is optimized to address distinct research questions, ensuring researchers can isolate and analyze targeted mechanisms without confounding variables.

In Vivo Models: Translational Relevance for Preclinical Development
As an experienced ICH animal model CRO, Ace Therapeutics offers a comprehensive suite of animal models across multiple species, including rodents and large-animal models—tailored to match the scale and translational needs of each study. Core in vivo models include:

Whole blood injection models: A gold standard for mimicking acute hematoma accumulation, these models allow precise control of hematoma volume and are widely used to evaluate interventions for swelling, hematoma expansion, and hemodynamic changes. Applied in both small animals (e.g., rat/mouse caudate nucleus injections) and large animals (e.g., pig/sheep frontal lobe or basal ganglia injections), they closely replicate clinical ICH's rapid blood accumulation.

Collagenase models: Inducing localized hemorrhage via microvascular rupture, these models offer flexibility in hematoma size control through dosage adjustment, suitable for studying both parenchymal and intraventricular hemorrhage.

Microballoon insertion models: Simulating the space-occupying effects of ICH, these models replicate increased intracranial pressure (ICP) and reduced cerebral blood flow (CBF)—critical contributors to acute brain injury.

When selecting the optimal model, Ace Therapeutics' team collaborates with researchers to align with study goals—whether focusing on acute vs. chronic hematoma phases, molecular vs. hemodynamic analysis, or efficacy testing of novel therapeutics. This tailored approach ensures that each model delivers maximum translational value, bridging the gap between preclinical research and clinical application.

With its comprehensive model portfolio, customization flexibility, and translational focus, Ace Therapeutics is positioned as a trusted partner for biotech companies, pharmaceutical firms, and academic researchers dedicated to advancing ICH therapeutics. By leveraging custom hemorrhagic stroke models and specialized CRO services, the research community can overcome preclinical barriers and move closer to ending the burden of hemorrhagic stroke.

About Ace Therapeutics
Ace Therapeutics is a leading provider of preclinical research models and CRO services for neurological disorders, with a focus on hemorrhagic stroke and ICH. By combining scientific expertise, technical innovation, and a client-centric approach, the company delivers high-quality, customizable research tools that drive translational research and therapeutic development.

Read the full story here: https://www.24-7pressrelease.com/press-release/531060/ace-therapeutics-leads-the-way-in-advancing-hemorrhagic-stroke-research-with-custom-in-vitro-and-in-vivo-models

Press Release Service and Press Release Distribution by 24-7 Press Release Newswire